David B. Roberts - 28 Feb 2025 Form 4 Insider Report for LEMAITRE VASCULAR INC (LMAT)

Role
President and Director, Director
Signature
/s/ Nathan Ulrich
Issuer symbol
LMAT
Transactions as of
28 Feb 2025
Net transactions value
-$18,646
Form type
4
Filing time
04 Mar 2025, 19:04:27 UTC
Previous filing
20 Feb 2025
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LMAT Common Stock Award $0 +685 +4.7% $0.000000 15,356 28 Feb 2025 Direct F1, F2
transaction LMAT Common Stock Options Exercise $0 +5 +0.03% $0.000000 15,361 28 Feb 2025 Direct F3
transaction LMAT Common Stock Tax liability $18,646 -203 -1.3% $91.85 15,158 28 Feb 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LMAT Dividend Equivalent Rights Options Exercise $0 -5 -28% $0.000000 13 28 Feb 2025 Common Stock 5 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent LMAT common stock acquired on February 28, 2025, upon settlement of a Performance Share Unit (PSU) award granted on December 8, 2023. The PSU award vests as follows: 25% upon determination by the Compensation Committee and the balance vests in equal annual installments from the grant date over the next three years.
F2 Each PSU represents a contingent right to receive one share of common stock upon vesting based on the attainment of performance goals.
F3 Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
F4 These shares represent shares withheld by the issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on December 8, 2023. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
F5 These dividend equivalent rights were released in connection with the vesting of a performance share unit (PSU) award granted on December 8, 2023. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.